Abstract
Prostate cancer remains one of the most common cancers in men and treatment options for patients with advanced or metastatic disease are limited. Immunotherapeutic approaches, such as passive or active immunotherapy, have been shown to be successful in treating some cancer patients. These rely on the identification of cancer specific antigens that can be targeted by the immune system or used to diagnose as early as possible and/or to monitor the disease and its progression. Several prostate cancer antigens have already been identified; these include Prostate-Specific Membrane Antigen (PSMA), Prostate Specific Antigen (PSA), Prostatic Acid Phosphatase (PAP), PAGE-4, PSP 94, differential display 3, prostate androgen-regulated transcript 1 and six-transmembrane epithelial antigen prostate-restricted antigens and these represent potential candidate for immunotherapy against prostate cancer. The following review describes the importance of these antigens with a particular emphasis to the PAP antigen and T21, a recently identified prostate cancer associated antigen, as very promising targets for prostate therapy.
Keywords: Prostate, peptides, immunotherapy, SEREX, T21
Current Cancer Therapy Reviews
Title: Overview of Prostate Biomarkers as Potential Targets for Immunotherapy
Volume: 4 Issue: 2
Author(s): Amanda K. Miles, Alistair Roger, Richard Parkinson, Robert C. Rees and Stephanie E.B. McArdle
Affiliation:
Keywords: Prostate, peptides, immunotherapy, SEREX, T21
Abstract: Prostate cancer remains one of the most common cancers in men and treatment options for patients with advanced or metastatic disease are limited. Immunotherapeutic approaches, such as passive or active immunotherapy, have been shown to be successful in treating some cancer patients. These rely on the identification of cancer specific antigens that can be targeted by the immune system or used to diagnose as early as possible and/or to monitor the disease and its progression. Several prostate cancer antigens have already been identified; these include Prostate-Specific Membrane Antigen (PSMA), Prostate Specific Antigen (PSA), Prostatic Acid Phosphatase (PAP), PAGE-4, PSP 94, differential display 3, prostate androgen-regulated transcript 1 and six-transmembrane epithelial antigen prostate-restricted antigens and these represent potential candidate for immunotherapy against prostate cancer. The following review describes the importance of these antigens with a particular emphasis to the PAP antigen and T21, a recently identified prostate cancer associated antigen, as very promising targets for prostate therapy.
Export Options
About this article
Cite this article as:
Miles K. Amanda, Roger Alistair, Parkinson Richard, Rees C. Robert and McArdle E.B. Stephanie, Overview of Prostate Biomarkers as Potential Targets for Immunotherapy, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310034
DOI https://dx.doi.org/10.2174/157339408784310034 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pro-Oncogenic Cell Signaling Machinery as a Target for Oncolytic Viruses
Current Pharmaceutical Biotechnology Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling
Current Cancer Drug Targets Mammalian Cell Competitions, Cell-in-Cell Phenomena and Their Biomedical Implications.
Current Molecular Medicine Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine Medicinal Properties of the Jamaican Pepper Plant Pimenta dioica and Allspice
Current Drug Targets MicroRNAs: Potential Diagnostic and Therapeutic Targets for Breast Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance
Current Cancer Drug Targets Non-allowed Pharmacologically Active Substances in Physical and Sexual Performance Enhancing Products
Current Neuropharmacology Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology A Review of IGF1 Signaling and IGF1-related Long Noncoding RNAs in Chemoresistance of Cancer
Current Cancer Drug Targets MicroRNAs as Main Players in the Pathogenesis of Chronic Lymphocytic Leukemia
MicroRNA Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer
Current Cancer Drug Targets Impact of Environmental Endocrine Disruption on the Reproductive System for Human Health
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Castration Resistant Prostate Cancer: From Emerging Molecular Pathways to Targeted Therapeutic Approaches
Clinical Cancer Drugs Editorial [Hot Topic: The Endothelin System: Vascular Targets for Therapy in Disease (Guest Editor: Michael R. Dashwood)]
Current Vascular Pharmacology Recent Advances in the Chemistry of Phthalimide Analogues and their Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Using Bioinformatics Techniques for Gene Identification in Drug Discovery and Development
Current Drug Metabolism MMPs in Ovarian Cancer as Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions
Current Cancer Drug Targets